EGFR and non-small cell lung carcinoma: In the past two decades, targeted therapies in NSCLC, mainly EGFR inhibitors such as erlotinib, gefitinib, afatinib and ALK and ROS-1 inhibitors like crizotinib, have developed rapidly and have shown high response rates.75